CytRx to investigate higher bafetinib doses in leukaemia
This article was originally published in Scrip
Executive Summary
CytRx is to investigate higher doses of its anticancer, bafetinib, after reporting positive preliminary results from a Phase II proof-of-concept trial with the product in patients with relapsed B-cell chronic lymphocytic leukaemia (B-CLL).